KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Receivables (2018 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Receivables for 7 consecutive years, with $30.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Receivables fell 15.81% year-over-year to $30.7 million, compared with a TTM value of $30.7 million through Sep 2025, down 15.81%, and an annual FY2024 reading of $36.5 million, up 51.7% over the prior year.
  • Receivables was $30.7 million for Q3 2025 at Aurinia Pharmaceuticals, down from $40.1 million in the prior quarter.
  • Across five years, Receivables topped out at $41.8 million in Q3 2022 and bottomed at $1.2 million in Q1 2021.
  • Average Receivables over 5 years is $24.4 million, with a median of $24.1 million recorded in 2023.
  • The sharpest move saw Receivables soared 1600.08% in 2022, then dropped 15.81% in 2025.
  • Year by year, Receivables stood at $15.4 million in 2021, then dropped by 12.53% to $13.5 million in 2022, then soared by 78.66% to $24.1 million in 2023, then skyrocketed by 51.7% to $36.5 million in 2024, then fell by 15.92% to $30.7 million in 2025.
  • Business Quant data shows Receivables for AUPH at $30.7 million in Q3 2025, $40.1 million in Q2 2025, and $40.4 million in Q1 2025.